Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy

World News: . []

LOS ANGELES Feb 05 2018 GLOBE NEWSWIRE -- NASDAQCAPR today announced that the US Food and Drug Administration FDA has granted CAP-1002 its lead investigational cell therapy for the treatment of Duchenne muscular dystrophy the Regene rative ...

More news and information about Capricor Therapeutics, Inc.

Published By:

Globe Newswire: 16:11 GMT Monday 5th February 2018

Published: .

Search for other references to "capricor" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us